Leerink Swann Downgrades Par Pharmaceutical (PRX) to Market Perform; Not Expecting Mylan (MYL) To Up The Ante
Tweet Send to a Friend
Leerink Swann downgraded Par Pharmaceutical (NYSE: PRX) from Outperform to Market Perform. Price target raised to $50.
Analyst, Jason ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Jason ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
